<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), or <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, are a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of <z:e sem="disease" ids="C0005956" disease_type="Disease or Syndrome" abbrv="">bone marrow disorders</z:e> characterized by progressive cytopenias and a propensity to evolve into <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The only curative strategy in the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is stem cell transplantation </plain></SENT>
<SENT sid="2" pm="."><plain>The advent of hypomethylating agents and, more recently, lenalidomide has changed the paradigm so that supportive treatment for patients who are not candidates for transplantation now includes drugs that may alter the natural history of the disease </plain></SENT>
<SENT sid="3" pm="."><plain>The remarkable results observed with lenalidomide in patients with del(5q) has promoted intense research into the pathobiology of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and new approaches to treatment; it is hoped that this success will be extended to <z:hpo ids='HP_0000001'>all</z:hpo> subtypes of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>